Czech innovative business estimates that sponsor-funded clinical trials saved the Czech healthcare system around €85 million in 2025
The Czech Republic is cementing its position as a leading destination for clinical research in Central Europe, even as European countries face mounting pressure from Asian rivals competing for pharmaceutical investment.
The State Institute for Drug Control (SÚKL), the country’s medicines regulator, reported a strong year for clinical activity in 2025, driven by the full implementation of the EU Clinical Trials Regulation and an expansion in advanced therapies, including gene and cell treatments.
“Last year represented a fundamental turning point for clinical trials in the Czech Republic,” said Tomáš Boráň, SÚKL’s director, presenting the annual data.
“We have fulfilled all legislative requirements and created a stable and transparent environment for clinical drug research,” he added. According to Boráň, Czechia remains “a respected partner in the European area”, and the regulator aims to further strengthen the country’s attractiveness for clinical trial sponsors while maintaining high standards of patient protection and data quality.
